MA61730A1 - Thérapie conjointe pour le traitement de crises épileptiques - Google Patents

Thérapie conjointe pour le traitement de crises épileptiques

Info

Publication number
MA61730A1
MA61730A1 MA61730A MA61730A MA61730A1 MA 61730 A1 MA61730 A1 MA 61730A1 MA 61730 A MA61730 A MA 61730A MA 61730 A MA61730 A MA 61730A MA 61730 A1 MA61730 A1 MA 61730A1
Authority
MA
Morocco
Prior art keywords
treatment
epileptic seizures
methods
conjoint therapy
compound
Prior art date
Application number
MA61730A
Other languages
English (en)
Inventor
Johnson, Jr
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MA61730A1 publication Critical patent/MA61730A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Dans certains modes de réalisation, la présente divulgation concerne des procédés et des utilisations pour traiter des crises épileptiques chez un être humain en ayant besoin, les procédés et les utilisations comprenant l'administration conjointe de n-[4-(6-fluoro-3,4-dihydro-1h-isoquinoline-2-yl)-2,6-diméthylphényl]-3,3-diméthylbutanamide (composé a) et d'un médicament antiépileptique (asm) à l'être humain en quantités qui sont thérapeutiquement efficaces lorsqu'ils sont administrés conjointement. La présente divulgation concerne également diverses méthodes améliorées de thérapie et d'administration du composé a.
MA61730A 2021-02-09 2022-02-09 Thérapie conjointe pour le traitement de crises épileptiques MA61730A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163147736P 2021-02-09 2021-02-09
PCT/US2022/015851 WO2022173853A1 (fr) 2021-02-09 2022-02-09 Thérapie conjointe pour le traitement de crises épileptiques

Publications (1)

Publication Number Publication Date
MA61730A1 true MA61730A1 (fr) 2024-01-31

Family

ID=80682617

Family Applications (1)

Application Number Title Priority Date Filing Date
MA61730A MA61730A1 (fr) 2021-02-09 2022-02-09 Thérapie conjointe pour le traitement de crises épileptiques

Country Status (16)

Country Link
US (2) US20220288057A1 (fr)
EP (1) EP4291185A1 (fr)
JP (1) JP2024506584A (fr)
KR (1) KR20240004238A (fr)
CN (1) CN117015379A (fr)
AU (1) AU2022218962A1 (fr)
CA (1) CA3207002A1 (fr)
CL (1) CL2023002323A1 (fr)
CO (1) CO2023011948A2 (fr)
GE (1) GEAP202416349A (fr)
IL (1) IL304918A (fr)
MA (1) MA61730A1 (fr)
MX (1) MX2023009313A (fr)
PE (1) PE20231856A1 (fr)
TW (1) TW202245743A (fr)
WO (1) WO2022173853A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005490A (es) 2019-11-08 2022-08-10 Xenon Pharmaceuticals Inc Metodos para el tratamiento de trastornos depresivos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174095A1 (en) 2006-08-23 2011-09-29 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
EP2461807A1 (fr) * 2009-08-05 2012-06-13 Convergence Pharmaceuticals Limited Co-thérapie pour le traitement de l'épilepsie et des troubles associés
US20190365709A1 (en) * 2018-03-21 2019-12-05 Sk Biopharmaceuticals Co., Ltd. Use Of [(1R)-1-(2-Chlorophenyl)-2-(Tetrazol-2-YL)Ethyl] Carbamate In Combination Therapy
WO2019217924A1 (fr) * 2018-05-11 2019-11-14 Xenon Pharmaceuticals Inc. Procédés d'amélioration de la biodisponibilité et de l'exposition d'un dispositif d'ouverture de canal potassique sensible à la tension
MX2022005490A (es) * 2019-11-08 2022-08-10 Xenon Pharmaceuticals Inc Metodos para el tratamiento de trastornos depresivos.
US11957675B2 (en) * 2021-02-09 2024-04-16 Xenon Pharmaceuticals Inc. Methods and uses for treating anhedonia

Also Published As

Publication number Publication date
GEAP202416349A (en) 2024-02-12
CA3207002A1 (fr) 2022-08-18
US20240408075A1 (en) 2024-12-12
WO2022173853A1 (fr) 2022-08-18
CO2023011948A2 (es) 2023-11-20
AU2022218962A1 (en) 2023-09-14
IL304918A (en) 2023-10-01
KR20240004238A (ko) 2024-01-11
MX2023009313A (es) 2023-08-16
US20220288057A1 (en) 2022-09-15
CN117015379A (zh) 2023-11-07
TW202245743A (zh) 2022-12-01
EP4291185A1 (fr) 2023-12-20
JP2024506584A (ja) 2024-02-14
PE20231856A1 (es) 2023-11-21
CL2023002323A1 (es) 2024-03-08

Similar Documents

Publication Publication Date Title
Dickey et al. Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model
Berbée et al. γ-Tocotrienol ameliorates intestinal radiation injury and reduces vascular oxidative stress after total-body irradiation by an HMG-CoA reductase-dependent mechanism
Rauch et al. The regulation of inflammation by interferons and their STATs
Rosenbaum et al. Discontinuation of statin therapy due to muscular side effects: a survey in real life
Chapman et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day− 1) in the treatment of cutaneous or lymphocutaneous sporotrichosis
MA56607A1 (fr) Méthodes de traitement de troubles dépressifs
MA30324B1 (fr) Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
MA52569B1 (fr) Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
PE20040751A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE DOSIS BAJAS DE UN INHIBIDOR DEL TNFalfa HUMANO
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
DE60127457D1 (de) Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
DE69534564D1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure-derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
KR20180094989A (ko) 노화 관련 인지장애 및 신경염증의 예방 및/또는 치료 방법
US20200297670A1 (en) Capsaicin Sequential Dosing Method for Treatment of Morton's Neuroma Pain
MA61730A1 (fr) Thérapie conjointe pour le traitement de crises épileptiques
Yang et al. Anti-epileptic and neuroprotective effects of ultra-low dose NADPH oxidase inhibitor dextromethorphan on kainic acid-induced chronic temporal lobe epilepsy in rats
Gundavarapu et al. A critical role of acute bronchoconstriction in the mortality associated with high-dose sarin inhalation: effects of epinephrine and oxygen therapies
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции
Ellis et al. Statins and coenzyme Q10
Bourcier et al. ß1-adrenergic blockers preserve neuromuscular function by inhibiting the production of extracellular traps during systemic inflammation in mice
ATE155343T1 (de) Verwendung von 2-(4-(-chlorophenyl)cyclohexyl>-3- hydroxy-1,4-naphtoquinon zur behandlung von krebs
MA56105B1 (fr) Ester isopropylique d'acide [((1r,2s,5r)-2-isopropyl-5-méthyl-cyclohexanecarbonyl)-amino]-acétique pour traiter la toux chronique
Ørnbjerg et al. FRI0378 DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DEPEND ON THE REASON FROM WITHDRAWAL FROM THE PREVIOUS TREATMENT?–RESULTS FROM THE EUROSPA RESEARCH COLLABORATION
Fournier et al. Losartan versus captopril in elderly patients with heart failure